Venous Thromboembolism Risk in Ischemic Stroke Patients Receiving Extended-Duration Enoxaparin Prophylaxis: Results From the EXCLAIM Study [Brief Reports]
Conclusion—
Extended-duration thromboprophylaxis with enoxaparin was associated with reduced venous thromboembolism risk and increased major bleeding in the subgroup of patients with ischemic stroke in the EXCLAIM study.
Clinical Trial Registration Information—
URL: http://clinicaltrials.gov. Unique Identifier: NCT00077753.
Source: Stroke - Category: Neurology Authors: Turpie, A. G. G., Hull, R. D., Schellong, S. M., Tapson, V. F., Monreal, M., Samama, M.-M., Chen, M., Yusen, R. D., for the EXCLAIM Investigators Tags: Cerebrovascular disease/stroke, Deep vein thrombosis, Anticoagulants Brief Reports Source Type: research
More News: Bleeding | Clinical Trials | Ischemic Stroke | Lovenox | Neurology | Pulmonary Thromboembolism | Stroke | Study | Thrombosis